Comparing the effectiveness of RALP and ORP
“I want to reiterate that this study doesn't necessarily say that 1 approach is better than the other, but it definitely does reinforce some advantages of robotic surgery that have been shown not just in this study, but in other studies as well,” says Peter Chang, MD, PhD.
In this video Peter Chang, MD, PhD, discusses the key takeaways from the Journal of Urology study, “Prospective multicenter comparison of open and robotic radical prostatectomy: The PROST-QA/RP2 consortium.” Specifically, he emphasizes how the efficacy of the prostatectomy relies on skill of surgeon and the individualized case itself. Chang is an assistant professor of surgery at Harvard Medical School and the director of the Prostate Cancer Care Center at Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.
